Long-term PPI Exposure Linked to Hyperparathyroidism in Seniors

This article originally appeared here.
Correlation persists regardless of concurrent oral bisphosphonate administration.
Correlation persists regardless of concurrent oral bisphosphonate administration.

(HealthDay News) -- Chronic proton pump inhibitor (PPI) exposure is associated with mild hyperparathyroidism in elderly adults, according to a study published in the Journal of the American Geriatrics Society.

Andrew M. Hinson, M.D., from the University of Arkansas for Medical Sciences in Little Rock, and colleagues examined the effect of PPIs with and without concurrent bisphosphonates (BPs) on parathyroid hormone (PTH), vitamin D, and calcium in a retrospective chart review of individuals aged 60 years and older. Data were included for 80 individuals meeting inclusion criteria.

The researchers found that, compared with no PPI exposure, chronic PPI exposure correlated with significantly higher PTH (65.5 versus 30.3 pg/mL; P < 0.001) and lower calcium (9.1 versus 9.4 mg/dL; P = 0.02). Compared with BP therapy alone, chronic PPI exposure with concurrent BP therapy was associated with significantly higher PTH (65.2 versus 43.4 pg/mL; P = 0.05) and lower calcium (9.2 versus 9.6 mg/dL; P = 0.04).

"Based on the present study, chronic PPI exposure in elderly adults is associated with mild hyperparathyroidism regardless of concurrent oral BP administration," the authors write.

Source

  1. Hinson AM. Wilkerson BM. Rothman-Fitts I, et al. Hyperparathyroidism Associated with Long-Term Proton Pump Inhibitors Independent of Concurrent Bisphosphonate Therapy in Elderly Adults. Journal of the American Geriatrics Society volume 63, Issue 10, pages 2070–2073.
Loading links....
You must be a registered member of Renal and Urology News to post a comment.